Experience

Mendel University in Brno

• Czechia
• Higher Education
• 300 - 400 Employee

• Professor

  • Jan 2020 - Present

  I have always enjoyed trying to understand and exploit molecular mechanisms in biology. From such beginnings, the great fascination of my academic career has been the design and creation of advanced therapeutics and diagnostics to address unmet medical need in the treatment of chronic diseases (such as cancer, diabetes, pain and some infectious diseases). Current active fields of research include nanomedicine and gene therapy, with a particular interest in achieving super enhanced functional delivery of therapeutic agents (such as DNA, siRNA, miRNA, mRNA, small molecules), and/or imaging agents (including MRI contrast agents and fluorophores), to target cells in vivo all by means of next generation synthetic lipid-based nanoparticles (LNPs). In addition, my research teams and I have also been returning to past interests concerning new theories of biological molecular recognition (Proteomic code - second genetic code) and the chemistry of stress. Show less



KP Therapeutics (Europe) s.r.o.

• Brno, Czech Republic

• Chief Scientific Officer

  • Jul 2020 - Present

  I have always been committed to the commercialisation of academic research output whenever possible. Therefore, I have a long standing strong personal interest in translating the fruits of academic research to market in the form of advanced therapeutic and diagnostics products. At Imperial College London, I helped found several academic spinout companies, beginning with Proteom Ltd in September 1999 and IC-Vec Ltd in December 2001. My latest spinout company is KP Therapeutics (Europe) s.r.o., that was founded in July 2020 with the aim of becoming a global leader in the design and implementation of precision therapeutic approaches (PTAs) for the treatment of cancers and other chronic diseases. PTAs are all based upon precision nanomedicines and/or precision therapeutic agents, for use alone or in combination with clinically proven imaging and irradiation techniques, and all derive from the best of my personal and collaborative academic research work over the past two decades involving a research spend of at least £30 million. My hope is that these PTAs have a genuine potential to revolutionise healthcare, disease treatments, change standards of clinical care, and transform the way patients are managed, so ultimately saving lives. Show less



Imperial College London

• Research Services
• 700 & Above Employee

• Professor of Organic Chemistry & Chemical Biology

  • Oct 2002 - Mar 2010

  Founding Director of the GTC

• Reader in Organic Chemistry and Chemical Biology

  • Oct 2000 - Sep 2002

• Lecturer

  • Oct 1990 - Sep 2000



Harvard University

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • Oct 1988 - Sep 1990



University of Cambridge

• United Kingdom
• Research Services
• 700 & Above Employee

• Postdoctoral researcher

  • Oct 1987 - Sep 1988